Phase 2a trial in 125 adults at high risk of post-stroke epilepsy after ischaemic stroke or intracerebral haemorrhage: eslicarbazepine acetate did not significantly cut unprovoked seizure, death or discontinuation at 6 months vs placebo (28% vs 37%); 5 deaths, all on drug.
RCTn = 125
Koepp et al. Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial